Canine Cancer Immunotherapy Network (K9CIN; U01 Clinical Trial Not Allowed)
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
AI Contract Overview
This contract seeks to support ongoing canine cancer immunotherapy clinical trials that serve as important models for human cancer treatment due to the similarities in disease development and immune response between pet dogs and humans. The initiative will fund a network of five U01 awards, including one Network Coordinating Center that facilitates collaboration and conducts limited research, and four awards focusing on conducting canine immunotherapy clinical trials using single or combination treatment approaches. These trials aim to evaluate novel and existing immunotherapeutic agents, leveraging the translatability of canine cancer trials to human applications while also providing potential benefits to the canine patients involved. The funding opportunity consolidates previous related solicitations to streamline applications and continue progress in the field, particularly in developing canine immunotherapeutics and analytics such as immune checkpoint inhibitors. The National Cancer Institute intends to sustain and accelerate advancements in this area, enabling timely assessment of new drugs, combinations, dosing, and sequencing in canine patients. This effort reflects a dual benefit, improving treatment options for dogs while generating valuable insights for human cancer therapies. The contract is managed by the NIH and underscores its commitment to translational cancer research through a coordinated network-based approach.
General Info
Agency
NAICS
Place of Performance
Not specifiedSet-Aside
Documents
(0)AI Contract Breakdown
Uniform Contract FormatNo contract breakdown available.
Cannot generate Contract Breakdown because no documents were found from this contract's source.
Timeline
Organization & Contact Information
Full Description
The goal of this RFA is to continue to support canine cancer immunotherapy clinical trials as indicators of safe and effective cancer treatments in humans. Pet dog patients develop cancer spontaneously and the courses of disease and treatment responses are similar to those in humans. Canine clinical trial results are translatable to humans. The assessment of responses to immunotherapy in immune-intact animals with existing cancers, such as pet dog patients, is the only way to preclinically take into account all facets of the immune response to cancer and to therapies. Ethically, pet dogs can benefit from the clinical trials by receiving cutting-edge therapies supported by the NIH, while providing important data informative to human disease. The network supported by this U01 RFA will consist of five U01 awards. One U01 will serve as a multifunctional Network Coordinating Center that will not only facilitate coordination across the Canine Cancer Immunotherapy Network (K9CIN) but will also perform limited research to support the network. Four U01 recipients will conduct canine clinical trials using immunotherapeutic agents alone or in combination with other treatment modalities.
Through this reissue Notice of Funding Opportunity, the National Cancer Institute intends to continue to support canine immunotherapeutic development as the field continues to grow, in part because of NIH funding. In the last five years, canine immunotherapeutics such as immune checkpoint inhibitors have become available as have canine analytics, development of which were partially supported by NCI. The goal is to maintain the momentum for further development of canine analytics and therapeutics and the ability to evaluate novel and repurposed drugs, treatment combinations, and treatment dosing and sequencing in pet dogs in a timely fashion. This NOFO consolidates the prior U01 (RFA-CA-21-050) and U24 (RFA-CA-21-051) funding opportunities to streamline the application process for continued support to K9CIN. Applicants have the option of submitting either for the Network Coordinating Center with limited research focus or for conducting canine cancer immunotherapy clinical trials and correlative studies. These important canine cancer-related activities will provide a valuable opportunity for NIH support to benefit humans and dogs, at both ends of the leash.
